Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425592 · ClinicalTrials.gov registry record
Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 223
- Enrollment target
NCT02425592 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 223 participants.
The verdict
NCT02425592 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
Study Summary
The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS). Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a MRI-US fusion prostate biopsy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2015-04 |
| Est. Completion | 2025-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02425592
The ClinicalTrials.gov registry entry for NCT02425592 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02425592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02425592 about?
NCT02425592 is a clinical study titled "Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)". The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS). Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a ...
What is the current status of trial NCT02425592?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2015-04. Estimated completion is 2025-05.
Who is sponsoring clinical trial NCT02425592?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.